Sherwin K. B. Sy

1.5k total citations
83 papers, 1.1k citations indexed

About

Sherwin K. B. Sy is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Sherwin K. B. Sy has authored 83 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pharmacology, 28 papers in Molecular Medicine and 21 papers in Epidemiology. Recurrent topics in Sherwin K. B. Sy's work include Antibiotics Pharmacokinetics and Efficacy (33 papers), Antibiotic Resistance in Bacteria (28 papers) and Pneumonia and Respiratory Infections (18 papers). Sherwin K. B. Sy is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (33 papers), Antibiotic Resistance in Bacteria (28 papers) and Pneumonia and Respiratory Infections (18 papers). Sherwin K. B. Sy collaborates with scholars based in United States, Brazil and China. Sherwin K. B. Sy's co-authors include Hartmut Derendorf, Luning Zhuang, Frederico Severino Martins, Mingming Yu, Maria Cristina Bronharo Tognim, Serubbabel Sy, Josmar Mazucheli, Huiming Xia, Peijuan Zhu and Charles A. Peloquin and has published in prestigious journals such as Blood, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Sherwin K. B. Sy

77 papers receiving 1.1k citations

Peers

Countries citing papers authored by Sherwin K. B. Sy

Since Specialization

Citations

This map shows the geographic impact of Sherwin K. B. Sy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherwin K. B. Sy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherwin K. B. Sy more than expected).

Fields of papers citing papers by Sherwin K. B. Sy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherwin K. B. Sy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherwin K. B. Sy. The network helps show where Sherwin K. B. Sy may publish in the future.

Co-authorship network of co-authors of Sherwin K. B. Sy

This figure shows the co-authorship network connecting the top 25 collaborators of Sherwin K. B. Sy. A scholar is included among the top collaborators of Sherwin K. B. Sy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherwin K. B. Sy. Sherwin K. B. Sy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Application of Quantitative 1H-NMR for the Determination of Melatonin and Vitamin B6 in Commercial Melatonin Products 2025 ·Molecules ·Xinyu Gao, (unknown), (unknown), (unknown), Mingming Yu, Sherwin K. B. Sy, Cong Wang, (unknown)	1
2	Quantification and discovery of quality control chemical markers for Shouhui Tongbian capsules by UPLC-MS/MS 2025 ·Analytical Methods ·J Y Zhang, (unknown), Zhen Huang, (unknown), Xintong Wang, (unknown), (unknown), Xianzhen Wang, Jingchun Yao, (unknown), Sherwin K. B. Sy, (unknown), Yang Hai	0
3	The impact of aztreonam–clavulanic acid exposure on gene expression and mutant selection using a multidrug-resistant E. coli 2025 ·Microbiology Spectrum ·(unknown), (unknown), (unknown), Jun Yan, Kexin Zhang, (unknown), Junyi Huang, (unknown), (unknown), (unknown), Sherwin K. B. Sy, Michael J. Lynch, Hongan Long, Mingming Yu	0
4	Clinical Pharmacology of Asciminib: A Review 2024 ·Clinical Pharmacokinetics ·Matthias Hoch, Felix Huth, Paul W. Manley, (unknown), (unknown), Ying Fei Li, Yunlin Fu, Sherwin K. B. Sy, (unknown), Apu Chakraborty, Florence Hourcade‐Potelleret	7
5	Population modelling of nilotinib exposure vs . longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model 2024 ·British Journal of Clinical Pharmacology ·Sherwin K. B. Sy, (unknown), Christelle Darstein, Yiqun Yang, Kohinoor Dasgupta, S. S. Kapoor, Matthias Hoch, (unknown)	1
6	Simultaneous Determination of Levo-tetrahydropalmatine and Naltrexonein Rat Plasma by LC-MS/MS and its Application in a PharmacokineticStudy 2024 ·Current Pharmaceutical Biotechnology ·(unknown), Sherwin K. B. Sy, Mingming Yu, Zhihua Lv, Meixing Yan	0
7	Comparative metabolomics reveal key pathways associated with the synergistic activities of aztreonam and clavulanate combination against multidrug-resistant Escherichia coli 2023 ·mSystems ·(unknown), Hai Yang, Lei Zhang, (unknown), Mingming Yu, Sherwin K. B. Sy, (unknown)	4
8	Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae 2023 ·Pharmaceutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Jiali Yue, Frederico Severino Martins, Peijuan Zhu, (unknown), (unknown), Mingming Yu, Sherwin K. B. Sy	6
9	Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of Riemerella anatipestifer in Ducks 2022 ·Microbial Drug Resistance ·(unknown), Ruili Zhang, Sherwin K. B. Sy, Zhizhong Li, (unknown), (unknown), (unknown), Jiayuan Zhang, Zhihua Lv, Jinsong Liu, Liting Qin, Mingming Yu	3
10	Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii 2022 ·Frontiers in Microbiology ·(unknown), (unknown), Jiayuan Zhang, (unknown), (unknown), Frederico Severino Martins, Zhihua Lv, (unknown), Mingming Yu, Sherwin K. B. Sy	17
11	Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling 2022 ·Clinical Pharmacokinetics ·(unknown), (unknown), Zhihua Lv, Peijuan Zhu, Charles Oo, Mingming Yu, Sherwin K. B. Sy	13
12	Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol 2018 ·Clinical Cancer Research ·Hope S. Rugo, Javier Cortés, Ahmad Awada, Joyce O’Shaughnessy, Chris Twelves, Seock‐Ah Im, Alison L. Hannah, Lin Lü, Sherwin K. B. Sy, (unknown), Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, Edith A. Perez	17
13	Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs 2018 ·International Journal of Mycobacteriology ·(unknown), (unknown), (unknown), (unknown), Sherwin K. B. Sy, Charles A. Peloquin, Hartmut Derendorf	65
14	Dermal pharmacokinetics of pyrazinamide determined by microdialysis sampling in rats 2017 ·International Journal of Antimicrobial Agents ·(unknown), (unknown), Juliana de Carvalho da Costa, Sherwin K. B. Sy, (unknown), (unknown), (unknown), Hartmut Derendorf	15
15	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model 2015 ·International Journal of Antimicrobial Agents ·Sherwin K. B. Sy, (unknown), (unknown), Eduardo Asín‐Prieto, Bernd Rosenkranz, Mark F. Cotton, Hartmut Derendorf, Steve Innes	11
16	Electroencephalogram effects of armodafinil: Comparison with behavioral alertness 2013 ·The Journal of Clinical Pharmacology ·Daniela J. Conrado, (unknown), Mingzhou Ding, Jean E. Cibula, Christoph N. Seubert, Sherwin K. B. Sy, Stephan Eisenschenk, Hartmut Derendorf	4
17	Use of a sparse sampling study design to assess transfer of tramadol and its O‐desmethyl metabolite into transitional breast milk 2008 ·British Journal of Clinical Pharmacology ·Kenneth F. Ilett, M. J. Paech, Madhu Page‐Sharp, Sherwin K. B. Sy, Judith H. Kristensen, Raymond Goy, (unknown), (unknown), (unknown)	42
18	A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic 2004 ·American Journal of Cardiovascular Drugs ·Sherwin K. B. Sy, (unknown)	3
19	Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations 2003 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), (unknown), Sherwin K. B. Sy, Qiang Jiao, Andrzej Wernicki, Abdul Mutlib, (unknown), S. E. Unger, Henry J. Pieniaszek	13
20	Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers 2002 ·The Journal of Clinical Pharmacology ·Henry J. Pieniaszek, Sherwin K. B. Sy, William F. Ebling, Michael J. Fossler, Valerie A. Cain, John Mondick, (unknown), David M. Kornhauser	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact